Author

P. Shrivastava-Ranjan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1

Frequent Co-Authors

P. Chatterjee· 2 shared A. Burroughs· 1 shared A. S. Laufer Halpin· 1 shared A. Tamin· 1 shared B. M. Calderon· 1 shared B. R. Mann· 1 shared C. F. Spiropoulou· 1 shared C. G. Albarino· 1 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

P. Chatterjee

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Potently neutralizing human monoclonal antibodies against the zoonotic pararubulavirus Sosuga virus

H. M. Parrington, N. Kose, E. Armstrong, L. S. Handal, S. Diaz, J. X. Reidy, J. Dong, G. B. E. Stewart-Jones, P. Shrivastava-Ranjan, S. Jain, C. G. Albarino, R. H. Carnahan, J. E. Crowe

The paper identifies potent human monoclonal antibodies against Sosuga virus, revealing epitope diversity and neutralization mechanisms.

bioRxiv · Nov 17, 2022Immunology

Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines

L. Wang, M. H. Kainulainen, N. Jiang, H. Di, G. Bonenfant, L. Mills, M. Currier, P. Shrivastava-Ranjan, B. M. Calderon, M. Sheth, B. R. Mann, J. Hossain, X. Lin, S. Lester, E. Pusch, , Davis

This study evaluates how well antibodies from mRNA vaccines neutralize SARS-CoV-2 variants, finding that Omicron shows the most escape but booster doses maintain moderate neutralizing activity.

bioRxiv · Nov 24, 2021Microbiology

Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (GS-441524)

M. K. Lo, P. Shrivastava-Ranjan, P. Chatterjee, M. Flint, J. R. Beadle, N. Valiaeva, R. Schooley, K. Y. Hostetler, J. Montgomery, C. F. Spiropoulou

This study evaluates the antiviral activity of ODBG-P-RVn, an orally available prodrug of remdesivir, against SARS-CoV-2 and other viruses in human airway cells, showing improved efficacy compared to GS-441524.

bioRxiv · Aug 6, 2021Pharmacology & Toxicology